USC Roski Eye Institute faculty use AI with aim of revolutionizing patient care

8459
https://keck.usc.edu/ophthalmology-usc-roski-eye-institute-artificial-intelligence/
Story Headline and Deck – USC News *
AI and Ophthalmology: USC Roski Eye Institute Faculty Aim to Revolutionize Patient Care

DECK: Dr. Melinda Chang and Dr. Benjamin Xu are two physicians exploring the use of artificial intelligence (AI) in ophthalmology to automate clinical tasks and improve patient care.
Body Copy *
The aging population of the United States is expected to experience a significant shortage of healthcare providers in the coming decades, particularly in the field of ophthalmology. However, some physicians and researchers are exploring the potential of using artificial intelligence (AI) to automate aspects of patient care. If successful, their research could enable healthcare providers to allocate medical resources more efficiently, prioritizing patients with more severe diseases.

At the USC Roski Eye Institute, Dr. Melinda Chang, an Assistant Professor of Clinical Ophthalmology specializing in pediatric neuro-ophthalmology, and Dr. Benjamin Xu, an Assistant Professor of Clinical Ophthalmology specializing in glaucoma, are leading research using AI. While their focuses differ, both doctors are interested in leveraging AI to automate clinical tasks, streamline healthcare services, and provide high-quality care for patients in need.

“Our primary use of AI is to assist with data analysis and determine if it outperforms humans in certain challenging tasks,” explained Dr. Chang.

 

Differentiating Minute Details
Dr. Chang’s research specifically aims to employ AI to distinguish between papilledema and pseudopapilledema in fundus photos. Papilledema is a serious neurological condition that can be linked to tumors or other abnormalities in the brain, while pseudopapilledema is a benign condition. However, differentiating between the two can be challenging when examining fundus photos, which capture images of the back of the eye.

“Identifying the exact diagnosis typically requires longitudinal patient follow-ups and testing, including MRI scans and lumbar punctures,” Dr. Chang said. “We aim to have an answer earlier, and that’s where AI steps in.”

Collaborating with Children’s Hospital Los Angeles, UCLA, Boston Children’s Hospital, and Stanford in a multi-center study, Dr. Chang provides fundus photos to an AI model trained to classify between the two diseases. Currently, the AI model’s accuracy ranges between 70% and 80%, and sensitivity is up to 90%, surpassing human performance.

“AI is essentially programmed to scrutinize minute details in photos to provide an exact diagnosis. I don’t believe AI can replace doctors; it serves more as an additional set of eyes,” Dr. Chang said.

Dr. Chang’s future objectives include expanding the study to involve more institutions, gathering additional data, exploring the integration of other imaging techniques like OCT to enhance the AI model’s accuracy, and ultimately developing an application that clinicians can utilize to evaluate fundus photos and facilitate appropriate patient triage.

 

Automating Glaucoma Detection
Dr. Xu’s lab is currently working on a major research initiative to automate the detection and referral of Los Angeles County (LAC) Department of Health Services (DHS) patients with glaucoma using AI and fundus photographs. The primary goal of the initiative is to develop AI algorithms that will transform care and improve access for the underserved, safety net patient populations of LAC DHS.

“Glaucoma is endemic among patients of LAC DHS, where it commonly leads to permanent, severe vision loss. The wait for a glaucoma evaluation typically takes more than six months, even when patients have severe disease,” Dr. Xu said. “This is a significant problem because valuable time is lost when these patients could have received sight-saving treatment.”

Dr. Xu has utilized AI in his research since 2017, at first to address the need for novel clinical tools to analyze optical coherence tomography (OCT) images and detect patients at high risk for glaucoma. “OCT provides high-quality images that are effective for identifying patients at risk for glaucoma. I ventured into the field of AI to automate the analysis of these images so that OCT can be used more conveniently by physicians.” Dr. Xu elaborated that analysis of some types of OCT images requires time and expertise that physicians often lack. His lab aims to develop tools that simplify this process for physicians to improve the quality and efficiency of glaucoma care.

Dr. Xu recently secured a two-year grant from the Southern California Clinical and Translation Science Institute (SC CTSI) and LAC DHS to support his ongoing research. The grant allows his lab to develop preliminary AI algorithms for implementation in LAC DHS glaucoma screening clinics. Success in this endeavor will enable Dr. Xu and his team to demonstrate that their bold ideas are feasible and seek additional funding from the federal government.

“It is crucial to emphasize the ambitious nature of this initiative in LA County. There are no other municipal health systems attempting a project of this scale,” Dr. Xu said. “Current challenges lie not in developing AI algorithms, but in implementing them. It requires merging laboratory research with real-world clinical practice. That is why this proposal is so exciting: we are leveraging data from tens of thousands of patients and directly giving back to the same patient communities by developing AI algorithms to serve them.”

 

Ethical Considerations
As the ethical considerations of AI have become an increasingly hot topic in 2023, both Dr. Chang and Dr. Xu were open about addressing the ethical concerns arising from the incorporation of AI into healthcare.

Dr. Xu emphasized a primary concern surrounding AI’s proficiency to generalize beyond the population from which its training data is obtained. “At present, our AI algorithm is developed using data from Los Angeles County Department of Health Services, where the majority of patients are Latino. While our algorithm may work effectively for Latino individuals, its performance may degrade when applied to individuals of other races and ethnicities. There should always be concern regarding potential biases that are latent due to unique attributes of data sources used to develop AI algorithms.”

Dr. Chang shared similar sentiments, underscoring the importance of AI’s ability to generalize across diverse populations. “That is why we have established partnerships with other medical sites nationwide and aspire to collaborate with even more to ensure a more diverse sample.”

Driven by these considerations and with the goal of establishing a large sample size at the forefront of their missions, both Dr. Chang and Dr. Xu are committed to discovering how AI can be harnessed for the greater good and the benefit of patients and healthcare professionals alike.

The post USC Roski Eye Institute faculty use AI with aim of revolutionizing patient care appeared first on USC News.

Even ‘safe’ air pollution levels can harm the developing brain, study finds

8472 https://keck.usc.edu/even-safe-air-pollution-levels-can-harm-the-developing-brain-study-finds/
Story Headline and Deck – USC News *
Even “safe” air pollution levels can harm the developing brain, study finds

In one of the first studies of its kind, researchers from the Keck School of Medicine of USC found that everyday air pollution can alter brain development patterns in adolescents.
Body Copy *
Air pollution is known to contribute to disease, which is why regulators such as the Environmental Protection Agency (EPA) set limits on emissions. But mounting evidence suggests that even pollution levels long thought to be safe can increase the risk of health problems, including in the brain.

Now, research from the Keck School of Medicine of USC, funded by the National Institutes of Health and the EPA, has shown that even levels of certain pollutants considered safe by the EPA are linked to changes in brain function over time. The study, just published in the journal Environment International, used brain scan data from more than 9,000 participants in the Adolescent Brain Cognitive Development (ABCD) study, the largest-ever nationwide study of youth brain health. Children exposed to more pollutants showed changes in connectivity between various brain regions. In some areas, they had more connections than normal; in other areas, they had fewer.

“A deviation in any direction from a normal trajectory of brain development–whether brain networks are too connected or not connected enough–could be harmful down the line,” said Devyn L. Cotter, MSc, a doctoral candidate in neuroscience at the Keck School of Medicine and first author of the study.

Communication between regions of the brain help us navigate virtually every moment of our day, from the way we take in information about our surroundings to how we think and feel. Many of those critical connections develop between the ages of 9 and 12 and can influence whether children experience normal or atypical cognitive and emotional development.

“Air quality across America, even though ‘safe’ by EPA standards, is contributing to changes in brain networks during this critical time, which may reflect an early biomarker for increased risk for cognitive and emotional problems later in life,” said Megan M. Herting, PhD, associate professor of population and public health sciences at the Keck School of Medicine and the study’s senior author.

Changes in brain connectivity

To explore the link between air pollution and brain development, Herting, Cotter and their colleagues analyzed functional MRI scans from 9,497 participants in the ABCD study. Baseline brain scans were collected from children, ages 9 to 10, and a subset of children had follow-up scans collected two years later, allowing researchers to observe how brain connectivity changed over time. In particular, they analyzed the salience, frontoparietal and default-mode brain networks, as well as the amygdala and hippocampus–key regions of the brain known to be involved in emotion, learning, memory and other complex functions.

Next, the researchers used EPA and other data to map air quality at each child’s residence, including levels of fine particulate matter (PM2.5), nitrogen dioxide (NO2) and ground-level ozone (O3). They then used advanced statistical tools to investigate how air pollution levels relate to changes in brain connectivity over time. In other words: are young brains developing differently when they are exposed to more pollution?

Greater exposure to PM2.5 was linked to relative increases in functional connectivity between regions, while more exposure to NO2 predicted relative decreases in connectedness. Exposure to higher levels of O3 was associated with greater connections within the brain’s cortex, but fewer connections between the cortex and other regions, such as the amygdala and hippocampus.

To rule out other factors that could explain differences in brain development, the researchers controlled for sex, race/ethnicity, parental education level, household income, urban versus rural location and seasonality, as air pollution varies across winter and summer months.

Tightening air quality rules

The findings could prompt regulators to consider brain health, in addition to lung and cardiometabolic heath, when they set or adjust recommendations for air quality. While the EPA proposed strengthening standards for PM2.5 earlier this year, guidelines for annual NO2 have not changed since they were first set in 1971.

“On average, air pollution levels are fairly low in the U.S., but we’re still seeing significant effects on the brain,” Cotter said. “That’s something policymakers should take into account when they’re thinking about whether to tighten the current standards.”

Cotter, Herting and their colleagues aim to look more closely at the chemical makeup of pollutants to determine how and why they cause harm in the brain, which could help further refine regulations. They also plan to continue using data from the ABCD study to analyze brain health over time.

“Long term, does this lead to risk for psychopathology that continues to ramp up during mid- to late- adolescence? How does this affect people’s trajectory of mental health?” Herting said.

About this study

In addition to Cotter and Herting, the study’s other authors are Claire E. Campbell, Kirthana Sukumaran, Rob McConnell and Hedyeh Ahmadi from the Department of Population and Public Health Sciences, Keck School of Medicine of USC; Daniel A. Hackman from the USC Suzanne Dworak-Peck School of Social Work; Jiu-Chiuan Chen from the Department of Neurology, Keck School of Medicine of USC; Kiros Berhane from the Department of Biostatistics, Columbia University Mailman School of Public Health; and Joel Schwartz from the Department of Environmental Health, Harvard T. H. Chan School of Public Health.

This work was supported by National Institutes of Health [NIEHS R01ES032295, R01ES031074, P30ES007048-23S1, 3P30ES000002-55S1] and the Environmental Protection Agency [RD 83587201, RD 83544101].

The post Even ‘safe’ air pollution levels can harm the developing brain, study finds appeared first on USC News.

Biosimilars drug market is helping to reduce medication prices, USC study finds

8450 your school/unit website *

Biosimilars Drug Market Isn’t Broken After All, USC Schaeffer Study Finds

Story Headline and Deck – USC News *
Biosimilars Drug Market Isn’t Broken After All, USC Study Finds

Researchers looked at cancer therapy trastuzumab (Herceptin) and found biosimilars bring competition to the market, with prices declining by more than half for some versions.
Body Copy *
The U.S. biosimilar drug market emerged in 2015 to provide safe, effective, and more affordable alternatives to existing biologic drugs, but it has been slow to develop compared with Europe.

Now, eight years into the U.S. experience with biosimilars, researchers at the USC Schaeffer Center have studied the cancer drug trastuzumab (Herceptin) and its five biosimilar entrants as an example of biosimilars’ potential to reduce drug prices. Published today in Health Affairs, the study is one of the first to look at several biosimilar competitors in terms of U.S. market share, price, and physician prescribing.

“With multiple biosimilar competitors entering the U.S. market quickly, trastuzumab is the best example to date of biosimilars fulfilling their promise to reduce biologic drug prices,” said study co-author Alice Chen, associate professor and vice dean for research at the USC Sol Price School of Public Policy and senior fellow at the USC Schaeffer Center. “In just three years, the trastuzumab market displayed important hallmarks of competition: doctors could choose among six products; new entrants rapidly captured market share from the originator; and prices steadily declined on all six options. Prices of some versions declined by more than half, and the originator lost half of the market.”

Researchers evaluated changes in average sales price, net price, and the extent to which the first biosimilar retained its advantage over later biosimilar entrants. Data show that the originator, Herceptin, began losing market share immediately after the first biosimilar, Kanjinti, entered the market. Herceptin continued to lose market share with subsequent entrants including Ogivri, Trazimera, Herzuma, and Ontruzant.

The data also show that while the existence of biosimilar options did not expand the total market for trastuzumab, multiple biosimilar products were viable and resulted in declining average sales price of all products.

Key Findings
By the second quarter of 2022, the biosimilars’ average sales price ranged from 28% to 58% of Herceptin’s first quarter 2019 average sales price; the biosimilars’ net prices ranged from 15% to 46% of Herceptin’s pre-competition net price.
Monthly costs for biosimilar trastuzumab were as low as $1,693 (average sales price) and $813 (net price) compared with the originator’s cost of $4,829 (average sales price) and $4,213 (net price).
Herceptin’s average sales price fell 21% from $101 to $80 per 10 milligrams.
Kanjinti maintained a strong and persistent “first-mover advantage” over the subsequent four biosimilar entrants. While subsequent entrants achieved a higher market share in eight states, Kanjinti maintained the majority market share among biosimilars in most states.
Hospital-based physicians prescribing trastuzumab tended to prescribe either the biologic or a biosimilar, but not both, whereas office-based physicians prescribed more evenly across the drug choices.
“Our analysis applies to a physician-administered drug under Medicare Part B, and provides the best evidence so far that biosimilars can reduce originator drug prices quickly, in the same way that generics reduce prices of small-molecule drugs,” said co-author Karen Van Nuys, executive director of the Value of Life Sciences Innovation program and a senior fellow at the USC Schaeffer Center. “Our findings support the growing body of evidence that biosimilars do in fact reduce biologic drug prices in the physician-administered market. Whether they can do the same in the retail drug market remains to be seen, as the industry brings more of these products to the market.”

Additional study authors included Katrina M. Kaiser, Laura Gascue, and Maria-Alice Manetas. Funding for this paper was provided by the USC Schaeffer Center.

The post Biosimilars drug market is helping to reduce medication prices, USC study finds appeared first on USC News.

To boost Latino participation in Alzheimer’s studies, don’t skimp on ‘personalismo,’ USC researcher says

Latinos make up 19% of the U.S. population, yet they represent only a small fraction of people enrolled in clinical trials for Alzheimer’s treatment. USC researcher Maria Aranda has recommendations for fixing that.


? Listen to our chat with Maria Aranda, a professor at the USC Suzanne Dworak-Peck School of Social Work, on USC’s Ideas in Action podcast.

? Read the Alzheimer’s Association story about Aranda’s new study.


“There has been too much onus, even blame, put on Latino individuals and families. But when researchers ignore micro-level details, it results in macro-level exclusion of Latinos from clinical trials,” said Aranda, who is the director of the outreach, recruitment and engagement core of the Alzheimer’s Disease Research Center at USC. “For example, Latinos’ expectation of personalismo — the quality and trustworthiness of interpersonal interactions — can be thwarted when providers’ (and by extension researchers’) time with them in the care visit or encounter is brief or hurried.”

Latinos and Alzheimer’s research: Addressing underrepresentation

To address the issue of underrepresentation of U.S. Latinos in Alzheimer’s research, Aranda and her co-authors have issued an urgent call to the research community to address this problem. Their study, just out in Alzheimer’s & Dementia: Translational Research & Clinical Interventions, outlines key steps:

  • Embed recruitment and research operations within Latino communities and settings.
  • Creatively address limited literacy in English and Spanish.
  • Make binding all diversity plans at the Food and Drug Administration for AD/ADRD (Alzheimer’s disease and Alzheimer’s disease related dementias) clinical trials.
  • Support national legislation promoting trial participation of underrepresented groups.

“Closing the racial and ethnic disparity gap in Alzheimer’s and Alzheimer’s-related dementia trials,” Aranda said, “is clearly good science.”

The post To boost Latino participation in Alzheimer’s studies, don’t skimp on ‘personalismo,’ USC researcher says appeared first on USC News.

Arterial plaque buildup in legs especially dangerous to Black patients

8453 https://news.keckmedicine.org/black-patients-with-plaque-build-up-in-arteries-in-the-legs-more-likely-to-have-a-stroke-heart-attack-or-amputation-than-white-patients/preview/e085557defb6db222e197072deafccf7e52d14cf
Story Headline and Deck – USC News *
Black patients with arterial plaque buildup in the legs more likely to have a stroke, heart attack or amputation than white patients
Body Copy *
LOS ANGELES — A new study from Keck Medicine of USC has uncovered significant racial disparities in the diagnosis, treatment and outcomes of peripheral artery disease (PAD) among Black and white patients in the United States.

PAD, which affects approximately eight to 12 million Americans and is associated with nearly half of the 150,000 yearly amputations in the U.S., is a potentially life-threatening condition in which the arteries that carry blood from the heart to the legs narrow or become blocked by the buildup of fatty plaque. This can lead to a heart attack, stroke or amputation of the affected limb.

“We discovered that Black patients are nearly 50% less likely to receive vascular interventions to potentially restore the blood flow than white patients, and consequently are at a disproportionately higher risk of a stroke, heart attack or amputation,” said David Armstrong, a podiatric surgeon specializing in limb preservation with Keck Medicine and an author of the study. “Additionally, Black patients tend to have more advanced PAD and are sicker at the time of diagnosis, indicating they may not be getting as timely medical attention as their white counterparts.”

PAD often starts out with no or mild symptoms, such as a leg cramp or muscle pain, and therefore often goes underdiagnosed.

Once detected, generally through a blood test, PAD is typically treated with medication to reduce the plaque in the arteries and through suggested lifestyle changes, such as increased exercise and a healthy diet. If these measures don’t work, physicians usually recommend a procedure known as revascularization. Revascularization either improves the blood flow to the arteries by using a balloon or stent to open them or reroutes the blood to another, healthier artery, which can reduce the risk of a cardiac incident or amputation.

The study discovered that Black patients are more likely to only receive medication and lifestyle change recommendations, while white patients also receive revascularization. “Our findings suggest Black patients are missing out on potentially limb- and life-saving treatments,” said Armstrong. “And because Black patients tend to be sicker at the time of diagnosis than white patients, they may actually be in more need of a revascularization than other patients.”

Armstrong and his colleagues used a large national database to compare rates of diagnostic testing, treatment patterns and outcomes after diagnosis of PAD among commercially insured patients in the United States from the years 2016 to 2021. They identified some 455,000 white patients and 96,000 Black patients. They then compared demographics, markers of disease severity and health care costs as well as patterns of medical management and rates of amputation and cardiovascular events among the two patient groups to reach their conclusions.

While the study did not analyze why disparities in the detection, treatment and outcomes of PAD between Black and white patients exist, one factor may be that Black patients are already at a higher risk of developing PAD, said Armstrong. He also hypothesizes that the inequalities may be due to broader systematic issues in health care such as unconscious bias or barriers to health care access for certain populations.

“We hope this study will encourage physicians to take these differences into account when diagnosing and treating PAD to ensure that vascular interventions are being equally provided to all patients,” he said. “We also urge health professionals to offer more routine screenings for PAD in Black patients.”

Additionally, Armstrong advises patients to proactively seek medical advice and testing if they have any symptoms related to PAD — leg cramping, pain, numbness, weakness or discoloration — and advocating to be considered for all treatment options after diagnosis.

The post Arterial plaque buildup in legs especially dangerous to Black patients appeared first on USC News.

USC Stem Cell’s journey toward 1,000 mini-kidneys begins with $1 million fund

8451 story on your school/unit website *

USC Stem Cell’s journey towards 1,000 mini-kidneys begins with $1 million from KidneyX

Story Headline and Deck – USC News *
USC Stem Cell’s journey towards 1,000 mini-kidneys begins with $1 million from KidneyX
Body Copy *
To help patients in need of transplants, artificial kidneys would have to function like their natural counterparts, but they wouldn’t necessarily have to look like them. With a new $1 million prize from the Kidney Innovation Accelerator, or KidneyX, a team of USC Stem Cell scientists led by Nils Lindstrom in collaboration with Leonardo Morsut are on a quest to build a kidney that resembles the real thing in function, but not in form.

“Nature has taught us that kidneys can come in an astounding diversity of forms,” said Lindstrom, who is the principal investigator for the grant and an assistant professor of stem cell biology and regenerative medicine at USC. “Whereas humans have two big kidneys, one of our largest mammalian cousins, the whale, has numerous kidneys working together and resembling a bunch of grapes. We aspire to follow a similar design in building an artificial kidney using human stem cells.”

With the ultimate goal of providing functional artificial organs for the more than 100,000 patients awaiting kidney transplants, Lindstrom and his incoming PhD student Connor Fausto teamed up with Morsut and his postdoctoral trainee Fokion Glykofrydis.

To this collaboration, the Lindstrom lab members will contribute a detailed understanding of how the human kidney develops before birth. Following these fundamental developmental principles, they’ve already succeeded in using stem cells to generate and assemble up to 500 artificial kidney filtering tubes, called nephrons, into pea-size discs called organoids. And even though the scientists cannot yet assemble one million nephrons, which is the number found in a single adult human kidney, whale anatomy demonstrates that lots of little kidneys can work equally well as two big ones.

“Just one thousand of these kidney organoids would contain 400,000 nephrons and amount to approximately half the number of nephrons found in each of your kidneys,” said Lindstrom.

However, for these organoids to functionally compensate for a failing human kidney, they need to connect them to the blood supply as well as to a urine drainage system. This is because nephrons function to filter the blood, reabsorb needed nutrients and fluids, and excrete unneeded ones into the bladder as urine.

This is where the Morsut lab members bring in their expertise in synthetic biology, a field dedicated to redesigning biological systems. The Morsut lab has engineered genetic circuits that can instruct human cells to assemble into specific patterns and shapes, such as the tube-like structures needed to connect the kidney organoids to blood input and urine output.

“When growing kidney organoids in a lab, they need a little extra coaxing to develop all of the necessary functional components such as the drainage system for collecting urine,” said Morsut, a co-investigator on the grant and an assistant professor of stem cell biology and regenerative medicine, and biomedical engineering at USC. “Our engineered genetic circuits give them this extra nudge, and allow us to control their architecture with a precision that we can’t achieve in a lab environment if we rely solely on stem cells’ natural ability to self-organize.”

This unorthodox approach is precisely the type of research that KidneyX is designed to support. As a public-private partnership between the US Department of Health and Human Services (HSS) and the American Society of Nephrology, KidneyX aims to accelerate innovation in the prevention, diagnosis, and treatment of kidney diseases.

“What KidneyX has recognized is that we need to think better, think bold, and think big to build artificial kidneys that are wearable or implantable,” said Lindstrom. “We hope our collaboration can transform our thinking about how artificial kidneys can be built and drained through synthetic cellular systems, and ultimately provide better therapeutic alternatives for patients with end-stage kidney disease.”

The post USC Stem Cell’s journey toward 1,000 mini-kidneys begins with $1 million fund appeared first on USC News.

Raising awareness for leading non-genetic cause of infant hearing loss is personal

8411

https://dworakpeck.usc.edu/news/nursing-professor-uses-personal-experience-to-raise-awareness-of-the-leading-non-genetic-cause
Story Headline and Deck – USC News *
Nursing professor uses personal experience to raise awareness for leading non-genetic cause of hearing loss in infants

Michelle Zappas discovered a gap in knowledge among health care professionals around the viral infection that caused her daughter’s hearing loss.
Body Copy *
Two years ago, Michelle Zappas, director of the Department of Nursing at the USC Suzanne Dworak-Peck School of Social Work, noticed developmental delays and language regression in her two-year-old daughter Margot. Her little girl had even stopped responding to her own name.

Zappas, a family nurse practitioner with experience in community healthcare settings, suspected early on that the cause might be the result of congenital cytomegalovirus (CMV) infection, the most common viral infection and leading non-genetic cause of hearing loss in infants born in the United States. For the next 24 months she fought for Margot’s doctors to consider this, and along the way realized there was a significant gap in knowledge among medical professionals – and the general public – about the potential effects of CMV.

She consulted with colleagues Sharon P. O’Neill, clinical associate professor at the Rory Meyers College of Nursing at New York University, and Courtney Rotz, adjunct professor in the Department of Nursing at USC Social Work, to help research and document a case report. The three nurse practitioners recently published their findings, “Congenital Cytomegalovirus Infection: A Case Report,” in the Journal of Nurse Practitioners.

“The fact that as a healthcare professional I went through this, and was dismissed by quite a few medical professionals, has made me very passionate about spreading the word about CMV,” Zappas said. “Not only to the public, but also to the medical community.”

Awareness not proportional to prevalence

Through their research, and Zappas’ personal experience, the authors discovered that the medical community mostly looks for CMV only in very extreme cases in newborns. But symptomatic newborns only account for 10% of CMV cases. Often, as in Margot’s case, newborns may be asymptomatic or have only one or two slight symptoms, and it is not unusual in these cases for newborns to have delayed or progressive hearing loss.

Zappas, O’Neill and Rotz explain in the case report that CMV is a relatively common illness. Many people are exposed to it, and those with robust immune systems do not experience much more than common cold-type symptoms. If a woman acquires CMV during pregnancy, she may be unaware of it. However, if it affects the fetus in utero, it can have neurodevelopment consequences, including hearing loss. Women who are primarily infected during pregnancy are more likely to give birth to neonates who are symptomatic and suffer long-term effects. The authors also point out that CMV is one of the leading causes of childhood disabilities, yet the awareness is not proportional to the prevalence.

There were signs of potential CMV that many of Margot’s doctors missed. Zappas had intrauterine growth restriction causing her daughter to be born very small. Margot also experienced slight delays in her gross motor skills, had some hearing and words early on but then regressed. Even with a medical background and the ability to navigate the health care system, Zappas was often dismissed as a “hysterical mom,” causing the eventual diagnosis for her daughter to be delayed.

“We, as medical personnel, need to be aware that the family may have a bigger insight into what’s going on,” Zappas said. “And the family needs to advocate for themselves and their children for whatever those needs are. We can all support that, even for people who do not have as many resources as I did.”

Zappas hopes the case report will also bring more awareness of CMV to the Deaf and Hard of Hearing (DHH) community.

Changing the conversation

Zappas joined the National CMV Foundation and its fight for education, research funding and implementation of a national program to screen every newborn for congenital CMV. Only seven states require CMV education for pregnant women and targeted newborn screening. Only Minnesota has enacted universal newborn CMV screening.

According to Zappas, while a vaccine is in the works, that should not preclude patient education of how CMV is spread and what the symptoms are during pregnancy or in a young infant or toddler. If caught early enough, anti-virals may delay or decrease hearing loss as well as other sequelae such as cerebral palsy and retinitis.

“It needs to be on people’s radar for any child that is having some speech and language delay, lagging in some of their gross motor or fine motor skills, or had a complicated birth or prenatal history,” Zappas said. “This case report is really for nurse practitioners to make this a part of our differential.”

The post Raising awareness for leading non-genetic cause of infant hearing loss is personal appeared first on USC News.

USC’s Paul Aisen, pioneering Alzheimer’s researcher, honored with Epstein Alzheimer’s Disease Director’s Chair

USC Trustee Daniel J. Epstein, left, USC President Carol L. Folt and Paul Aisen celebrate as Aisen is named the inaugural holder of the Epstein Alzheimer’s Disease Director’s Chair.

USC’s Alzheimer’s Therapeutic Research Institute (ATRI) in San Diego hosted the chair installation ceremony, which recognized and honored Aisen’s decades of work leading teams toward more effective treatments for Alzheimer’s disease.

The Director’s Chair was endowed by the Epstein Family Foundation as another generous gift in a series of significant donations catalyzing Alzheimer’s research in Southern California.

The post USC’s Paul Aisen, pioneering Alzheimer’s researcher, honored with Epstein Alzheimer’s Disease Director’s Chair appeared first on USC News.

USC’s Paul Aisen, pioneering Alzheimer’s researcher, honored with Epstein Alzheimer’s Disease Director’s Chair

University

USC’s Paul Aisen, pioneering Alzheimer’s researcher, honored with Epstein Alzheimer’s Disease Director’s Chair

An international leader in Alzheimer’s disease research for over 30 years, Aisen is recognized with the highest academic honor at the Keck School of Medicine of USC.

June 09, 2023

Michael Price, Leigh Hopper

Paul Aisen, the founding director of USC’s Alzheimer’s Therapeutic Research Institute and a professor of neurology at the Keck School of Medicine of USC, was honored Friday as the inaugural recipient of the Epstein Alzheimer’s Disease Director’s Chair.

Aisen’s receipt of the honor — the highest academic honor at the Keck School — was the capstone moment of an extraordinary effort by USC Trustee Daniel J. Epstein and his family to accelerate the search for Alzheimer’s treatment and a cure. Colleagues, university leaders, family and friends crowded the San Diego event to share their appreciation for Aisen’s work in pushing the limits of what is known about the disease.

Defeating this disease is really one of the most daunting moonshots in medicine today.

Carol L. Folt, USC president

“Defeating this disease is really one of the most daunting moonshots in medicine today,” said USC President Carol L. Folt, characterizing Aisen and Epstein as ambitious problem-solvers dedicated to making a difference in the health and well-being of others. “But [Epstein’s] optimism and dedication have always enabled the best to do cutting-edge research, and this record of success continues with this new chair and with the work that all of you do.”

Aisen echoed Folt’s recognition of the role of teamwork: “Everybody in this room has a common mission of accelerating the development of effective treatments. What allows us to accomplish what we’ve accomplished is having everybody here together in an academic environment, supported by a fabulous university, working on innovation, collaboration, data sharing and moving the field forward.”

An unusual gift

Galvanized by a family loss — Epstein’s twin brother lived for 15 years with Alzheimer’s disease — the Epstein Family Foundation announced a $50 million joint gift to USC and the University of California, San Diego, in January 2022. The family made the unusual stipulation that the donation, split evenly, foster collaboration between the two institutions.

The family also established the USC Epstein Breakthrough Alzheimer’s Research Fund, which funds innovative, interdisciplinary research projects across USC that advance the development of new therapies and preventive measures for Alzheimer’s disease.

Our family’s support for Alzheimer’s research is intended to inspire others and generate real impact.

Daniel J. Epstein, USC trustee

“Our family’s support for Alzheimer’s research is intended to inspire others and generate real impact,” Epstein said. “We hope our commitments resonate with those who have the means to contribute to the cause — we urge them to look at their resources and say, ‘I want to help, too.’ Funding can accelerate promising research. Above all, it can shorten the time until we see more effective treatments and therapeutics, which we’re on the verge of, right now.”

Epstein, who earned his bachelor’s degree in engineering from the USC Viterbi School of Engineering in 1962, has served as a USC trustee for two decades. He is the founder of the San Diego-based ConAm group of companies. A longtime champion of USC initiatives, he traces his success to his USC education.

In 2021, Epstein and his wife, Phyllis, contributed $14 million to his namesake department at USC Viterbi in industrial and systems engineering. The gift was part of $25 million in total support that he has contributed to advance industrial and systems engineering research, teaching and learning.

Linked by loss

Like the Epsteins, Aisen has a personal tie to Alzheimer’s: His maternal grandmother died from the disease.

His clinical interest in the disease goes back to his time at Mount Sinai Medical Center in New York, where he served as chief medical resident. It was there, in the late 1980s, that some of the first attempts at treating memory loss took place.

In 1999, Aisen founded the Memory Disorders Program at Georgetown University, a clinical and research program for Alzheimer’s disease and related disorders. After many years of basic research studies, he became founding director of USC’s Alzheimer’s Therapeutic Research Institute in 2015. His work deepened scientific understanding of the crucial early years before symptoms manifest, which could offer an important window for potential treatments.

Under Aisen’s leadership, ATRI organizes and conducts rigorous trials investigating potential treatment avenues for Alzheimer’s disease — supported by millions of dollars in federal funding as well as contracts with private industry. On Friday, an FDA advisory panel unanimously endorsed the clinical benefits of the Alzheimer’s drug lecanemab, moving it forward for consideration for full FDA approval. ATRI played a pivotal role in advancing the treatment, with Aisen as the senior investigator for the clinical trial.

At least 6 million people in the United States are living with this debilitating and ultimately fatal brain disorder, and the situation is likely to worsen. As the U.S. population ages, the number of Americans suffering from Alzheimer’s could reach 14 million by 2060, according to the Centers for Disease Control and Prevention.

Aisen’s efforts unite Alzheimer’s researchers across the country. ATRI oversees the Alzheimer’s Clinical Trials Consortium, which centralizes resources and facilitates the sharing of expertise to accelerate the development of effective interventions.

Aisen and his team also are key partners in running a comprehensive training program (IMPACT-AD) to educate and diversify the next generations of clinical trial professionals.

Folt noted that Aisen’s favorite hobby is astrophotography — taking pictures of the night sky or objects in space.

“It’s really the perfect hobby: The glimmer of stars are much like the pulsing neurons of the human brain,” Folt said. “And I know you have made it your life’s work to assure that these constellations of light that power our emotions and thoughts never dim with the onset of Alzheimer’s.”

The post USC’s Paul Aisen, pioneering Alzheimer’s researcher, honored with Epstein Alzheimer’s Disease Director’s Chair appeared first on USC Today.

How the mung bean’s evolution provides cultivation clues for climate change

8437

Unraveling the Historic Journey of the Mung Bean: A Tale of Evolution, Migration and Climate Adaptation

The mung bean, commonly known as green gram, has played a pivotal role as a cheap protein source in regions where access to meat is limited. Spanning over 4,500 years, the cultivation of this humble legume has sustained civilizations throughout its history. While its migration routes and cultivation expansion have been a mystery, a new study by researchers at USC Dornsife College of Letters, Arts and Sciences that was published in eLife reveals insights into the circuitous odyssey of this resilient crop.

The study, co-led by Sergey Nuzhdin, professor of biological sciences at USC Dornsife, employed cutting-edge genomic techniques to trace the evolutionary trajectory of the mung bean. The team analyzed mung bean seeds from three global seed banks, including the Australian Diversity Panel, the World Vegetable Center in Taiwan and the Vavilov Institute of Plant Industry in Russia.

The research unveiled a distinctive path of cultivation and shed light on the factors influencing its expansion. Contrary to previous assumptions — based on the geographical proximity between South and Central Asia — genetic evidence suggests that the mung bean first spread from South Asia to Southeast Asia, and then finally reached Central Asia, including Western China, Mongolia, Afghanistan, Iran and Russia.

Adapting to climate
Nuzhdin and his team of international scientists used an interdisciplinary approach that looked at population information, environmental conditions, empirical field and laboratory investigation, and historical records from ancient Chinese sources. Through this analysis, they discovered that divergent climatic conditions and farming practices across Asia shaped the mung bean’s unique trajectory, not deliberate human cultivation choices.

Nuzhdin was surprised that the evolution was not solely driven by human activity through domestication but instead was intricately intertwined with the mung bean’s adaptation to diverse climates encountered throughout its journey.

What the research unraveled was the existence of two distinct adaptations of the mung bean, each favored in specific geographic locations. The southern variant, originating in South Asia before 1068-107 CE, is characterized by larger seeds, favoring higher yields in regions with scorching climates. In contrast, the northern variant, originating in northern China around 544 CE exhibited drought tolerance and a short vegetative period during the summer planting season. The mung bean later spread to the rest of China and Southeast Asia including Cambodia, Indonesia, the Philippines, Thailand, Vietnam and Taiwan.

Genetic variations
While the study’s historical revelations are compelling in their own right, their implications have relevance to new ways of breeding crops. The mung bean’s genetic makeup, including its short growing season and resilience to extreme heat, hold significant potential for mitigating the impact of climate change on agriculture. Particularly in Southeast Asia, where prolonged heat waves and the severity and impact of flooding threaten valuable agricultural areas, these genetic variants could prove to be a game-changer in the face of climate change.

“Our findings offer a critical roadmap for breeders aiming to enhance mung bean production in the face of climate change predictions, especially in the southern regions. This fundamental research holds immense importance in guiding the selection of genetic materials for breeding programs,” Nuzhdin said.

About the study:
The study, “Environment as a Limiting Factor of the Historical Global Spread of MungBean,” was published in eLife. The USC components were funded by the United States Agency for International Development and the Zumberge Foundation. Funding was also provided by the Ministry of Science and Technology, Taiwan; the Australian Center for International Agricultural Research; the strategic long-term donors to the World Vegetable Center; The Republic of China (Taiwan); the UK government; Germany; Thailand; Philippines; Korea; and Japan. The Russian Scientific Fund Project and the Ministry of Science and Higher Education of the Russian Federation also contributed.

The post How the mung bean’s evolution provides cultivation clues for climate change appeared first on USC News.